Takeda said Tuesday its trial of darvadstrocel in the treatment of complex Crohn’s Perianal Fistulas didn’t meet its primary endpoint based on topline data.
You are here: Home / Top Stories / Dow Jones Newswires: Takeda trial for Crohn’s Perianal Fistulas treatment misses primary endpoint